Searched for
MANKIND PHARMA SHARE PRICE TARGET
Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...- Micron Technology stock price jumps on Monday, shares up nearly 300 per cent for 2026U.S. Stock Market today: Micron Technology shares moved higher in premarket trading on Monday. AI-driven optimism has supported Wall Stree...
- Top Nifty50 stocks analysts suggest buying in this volatile weekStock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, ...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Sell or Hold: Citi maintains buy on Cipla; Motilal Oswal recommends buy on RIL post AGMBrokerages remain bullish on Cipla and Reliance Industries, citing strong growth drivers and attractive valuations. Citi highlights regulat...
- Stock Radar: Eicher Motors stock breaks out of 2-month consolidation phase; what should investors do?Eicher Motors has broken out of a two-month consolidation phase, with experts suggesting a target of Rs 8,000 for short-term traders. The s...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- Stock Radar: Trent broke out from an inverted head & shoulder pattern; time to buy?Trent Ltd stock has broken out of a bullish reversal pattern. Experts recommend buying the stock for a target of Rs 3,500 in the next one t...
- Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
- Robinhood stock soars despite layoffs – Why Wall Street is bullishRobinhood shares rallied after announcing a 10% workforce reduction, as investors viewed the move as a cost-efficiency strategy. Strong tra...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsFrom a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...
- Stock Radar: MRPL bounces back after forming double bottom formation; stock still down 25% from highs – should you buy?Mangalore Refinery and Petrochemicals Ltd stock is showing positive signals. A double bottom formation on daily charts indicates a potentia...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 millionZydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...
- Nomura raises Adani Ports share price target by 12%. Here are 3 major reasons whyNomura has raised its target price on Adani Ports and Special Economic Zone to Rs 2,080 from Rs 1,850, while retaining its Buy rating. The ...
- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
- Buy, Sell or Hold: RIL remains Morgan Stanley's top pick; remains underweight on Oil IndiaBrokerages remain selective on India's energy sector, favouring companies with strong growth drivers and attractive valuations. Morgan Stan...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
Load More
